Journal of Hematology & Oncology
Overview
The Journal of Hematology & Oncology is a peer-reviewed medical journal that focuses on the latest advancements in the field of hematology and oncology. It publishes high-quality research articles, reviews, and case reports, covering a wide range of topics including diagnosis, treatment, and management of hematological and oncological disorders. The journal serves as a valuable resource for healthcare professionals, researchers, and students interested in staying updated with the latest developments in these fields.
Details
Details
Abbr.
J Hematol Oncol
Publisher
Biomed Central
Start
2008
End
Continuing
e-ISSN
1756-8722
Country
United Kingdom
Language
English
Specialties
Oncology
Hematology
Hematology
Metrics
Metrics
h-index / Ranks: 1534
144
SJR / Ranks: 130
7522
CiteScore / Ranks: 105
38.40
JIF / Ranks: 87
28.5
Recent Articles
1.
Fu L, Zhou X, Zhang X, Li X, Zhang F, Gu H, et al.
J Hematol Oncol
. 2025 Mar;
18(1):29.
PMID: 40069858
Lymphoma, a malignant tumor derived from lymphocytes and lymphoid tissues, presents with complex and heterogeneous clinical manifestations, requiring accurate patient classification for appropriate treatment. While invasive pathological examination of lymph...
2.
Bu Q, Zhu H, Chen W
J Hematol Oncol
. 2025 Mar;
18(1):28.
PMID: 40055824
Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is...
3.
Ding Y, Bai Y, Chen T, Chen S, Feng W, Ma S, et al.
J Hematol Oncol
. 2025 Mar;
18(1):27.
PMID: 40055736
Background: Pancreatic cancer is one of the most malignant cancers, and limited therapeutic options are available. The induction of ferroptosis is considered to be a novel, promising strategy that has...
4.
Lian J, Yue Y, Yu W, Zhang Y
J Hematol Oncol
. 2025 Mar;
18(1):25.
PMID: 40045392
No abstract available.
5.
Li N, Sheng J, Zhu H
J Hematol Oncol
. 2025 Mar;
18(1):26.
PMID: 40045307
Degrader therapies have garnered significant attention for their innovative approach to targeting and eliminating malignancy-associated proteins, holding promise for improving outcomes for patients with relapsed or refractory (R/R) hematological malignancies,...
6.
Wu Y, Yan Y, Guo Y, Niu M, Zhou B, Zhang J, et al.
J Hematol Oncol
. 2025 Mar;
18(1):24.
PMID: 40038780
Background: Despite the success of immune checkpoint inhibitors (ICIs) in multiple malignant tumors, a significant proportion of patients remain unresponsive to treatment. Radiotherapy (RT) elicits immunogenic antitumor responses but concurrently...
7.
Kong R, Liu B, Wang H, Lu T, Zhou X
J Hematol Oncol
. 2025 Mar;
18(1):22.
PMID: 40025557
Natural killer cells, integral to the innate immune response, exhibit the inherent capacity to identify and eliminate cancer cells without prior exposure, positioning them as prime candidates for immunotherapeutic strategies....
8.
Zheng H, Xian H, Zhang W, Lu C, Pan R, Liu H, et al.
J Hematol Oncol
. 2025 Mar;
18(1):23.
PMID: 40025529
B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell...
9.
Qin L, Lai Y, Zhao R, Wei X, Weng J, Lai P, et al.
J Hematol Oncol
. 2025 Feb;
18(1):21.
PMID: 39994767
No abstract available.
10.
Tan S, Yang W, Ren Z, Peng Q, Xu X, Jiang X, et al.
J Hematol Oncol
. 2025 Feb;
18(1):20.
PMID: 39972384
In the present era, noncoding RNAs (ncRNAs) have become a subject of considerable scientific interest, with peptides encoded by ncRNAs representing a particularly promising avenue of investigation. The identification of...